VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...
BioNxt's lead pipeline product for MS is a proprietary sublingual (thin-film) formulation of Cladribine, offering an innovative alternative to traditional oral tablets. This next-generation delivery ...
iX Biopharma Ltd, a homegrown specialty pharmaceutical company, has announced the results of BUP001, a pharmacokinetic study of its novel sublingual buprenorphine wafer, BnoX. BnoX, which uses the ...
Sublingual NAD+ is the new gold standard for daily NAD+ supplementation, without the need for precursors The study consisted of 3 parts: 2 single-dose PK studies and a multiple-dose PK study, ...
CHICAGO — A novel sublingual formulation of buprenorphine-naloxone has a significantly preferred taste and overall acceptability compared with a commercially available film form of the drug, which is ...
Sublingual NAD+ is the new gold standard for daily NAD+ supplementation, without the need for precursors SINGAPORE, Sept. 2, 2024 /PRNewswire/ -- iX Biopharma (the "Company"), a specialty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback